|Bid||35.50 x 900|
|Ask||40.68 x 1200|
|Day's Range||37.97 - 41.95|
|52 Week Range||37.97 - 118.14|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||99.44|
Subscribe to Yahoo Finance Plus to view Fair Value for FATELearn more
Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Antigen Binding Domain of FT536 has been Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Six-arm Phase 1 Clinical Study to Evaluate Multi-dose, Multi-cycle Treatment Schedule of FT536 as Monotherapy and
Investment company MainStay VP Small Cap Growth Portfolio (Current Portfolio) buys Option Care Health Inc, Leslies Inc, Kratos Defense & Security Solutions Inc, 908 Devices Inc, SelectQuote Inc, sells Globant SA, Asana Inc, The Hain Celestial Group Inc, SiTime Corp, Vroom Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, MainStay VP Small Cap Growth Portfolio.
CFO of Fate Therapeutics Inc (30-Year Financial, Insider Trades) Edward J Dulac Iii (insider trades) sold 15,977 shares of FATE on 12/20/2021 at an average price of $60 a share.